RMDs. A learning partnership should be created between undergraduate medical students/healthcare professionals and the patient experts. Methods: CYPLAR approached the Swedish Rheumatism Association for collaboration in order to implement the Patient Expert Project in CYPLAR.Funding was received from the EULAR Knowledge Transfer Programme. The collaboration was planned to consist of two meetings, one in Sweden and one in Cyprus. The visit of the Swedish delegation took place in October 2016. Eight patients participated in the training. The training was made through workshops by the delegates from both organizations together with a Professor of rheumatology and a communication lecturer at the St George's University of London in Nicosia's establishments. Medical students were also involved in discussing their experience in being educated by patients. The programme also involved practice of joint examinations. The workshop was evaluated by the participants on the final day. After the workshop was concluded delegates spent a day discussing the event together. The programme was evaluated, and a future plan of action decided upon.
Conclusions:
The implementation of the patient expert programme was successful.10 new Patient Experts are now available in CYPLAR.The next generation of health professionals will benefit and get a larger understanding of RMD's and in the end, the patients will benefit because the health care staff has a greater knowledge. Background: "Rheumatism amongst young people, is that really a thing?" "Isn't rheumatism something that only old people have?" "You seem so happy and so active, surely you can't be in pain?" These are all questions that young people with rheumatism have to listen to, and answer every day. Yes, it's possible to have rheumatism even as a young person, and to be in pain, even though we're not letting it show. We know adjustment is possible, and that we can live our life to the fullest and follow our dreams, despite rheumatism. But sometimes it demands some extra understanding from the people around us. That's what we wanted to recognize, and created a campaign together with AbbVie. Objectives: It can be hard to understand and fully grasp something you can't see, something that is invisible. But as young people with rheumatism, we have to live and deal with our swollen joints, with the pain and the fatigue, and with the side effects of our medication. None of which should be questioned. We recognized that this was an issue for most people with rheumatism, and especially young people. Therefore, we wanted to start a conversation about how it is to go through life with an invisible disability. The main purpose with our campaign was to acknowledge the fact that you can't always tell whether or not a person has a diagnosis, or is in pain. We also wanted to show young people with rheumatism that they are not alone in their situation. Methods: We searched for young people with rheumatism in different ages and with different diagnoses. Each person in the campaign is presented in two different photos. One standard full-portrait photo in front of a white background, just showing who they are. One person held a basketball to show off her love for the sport, another one was wearing her dancing shoes and so on. The other photo is instead set in a complete dark room, with the person posing in the same way but this time with their rheumatism-affected areas lit up. We used glow in the dark-body paint and a UV-light to create this effect. Each pair of photos is put together with the person's story about their passion in life and what it's like to live and deal with an invisible disability. The campaign was released on October 12th 2016, on World Arthritis Day, with an event at Astrid Lindgren's children's hospital in Stockholm. The photos were printed and presented on large boards together with the personal stories. The first photo of the campaign, a group photo of everyone participating, was also posted on our social media on October 12th and then one pair of photos was posted every day during the following week. People were also told to share their own stories under the hashtag #synsintefinnsinte Results: The campaign ended up being our organization's most successful campaign to this date. The spread was especially great on Facebook, with the first post reaching nearly 50'000 people and the other posts reaching between 3'500 and 25'000 people every day. The campaign had more likes and shares on both Facebook and Instagram than any of our other campaigns has had so far. The opportunity to show the photos at Astrid Lindgren's children's hospital also brought health care into the campaign and attracted great attention on site. The photos combined with the personal stories make a powerful statement. We managed to show young people with rheumatism that they are not alone in their situation, and we look forward to the conversation continuing on at #synsintefinnsinte Background: Recently, a global OMERACT/EULAR ultrasound (US) synovitis score (GLOESS) combining grey-scale (GS) and power-Doppler (PD) scores has been proposed as a novel measurement tool to assess disease activity and response to therapy in patients with rheumatoid arthritis (RA) 1, 2 . However, the ability of GLOESS to differentiate patients with different states of disease activity vs. remission in standard clinical care is not known. Objectives: To assess the ability of GLOESS to discriminate between different clinical states of activity vs. remission in RA patients, and to compare clinical, GLOESS and PD US remission criteria and scores in a cross-sectional study. Methods: Eighty RA patients from 3 centres were recruited at consecutive clinical visits: 50% were in remission and 50% had active RA according to Simple Disease Activity Index (SDAI). SDAI, Clinical Disease Activity Index (CDAI), 28-joint Disease Activity Score (DAS 28CRP), Health Assessment Questionnaire (HAQ), ACR/EULAR remission criteria were assessed. An independent investigator unaware of clinical results performed all US joint examinations of 26 joints. GLOESS, PD, and GS US sum scores per patient were assessed using OMERACT definitions. PD US remission was defined as the PD sum score =0. GLOESS remission was defined as GLOESS score ≤1 thereby also including possible GS grade 1. Results: PD US remission was observed in 38 (48%) patients and GLOESS remission in 16 (20%) patients. SDAI (r=0.24; p=0.03) and CDAI (r=0.23; p=0.04) but not DAS28CRP (r=0.21; p>0.05) were weakly correlated with GLOESS scores in the whole joint set. SDAI (r=0.41; p<0.001), CDAI (r=0.40; p<0.001), and DAS28CRP (r=0.40; p<0.001) were moderately correlated with PD activity in the whole joint set. A minority of patients were classified both in GLOESS remission and in clinical remission according to SDAI (n=10), to CDAI (n=10), to DAS28CRP (n=10) and to ACR/EULAR 2011 (n=7). Less than one third of patients were classified both in PD US remission and in clinical remission according to SDAI (n=22), to CDAI (n=26), to DAS28CRP (n=27) and to ACR/EULAR 2011 (n=21). The proportion of patients in clinical remission was significantly different according to the definition considered: while 50% of the patients (n=40) were classified in remission according to SDAI, 58% (n=46) were classified in remission according to DAS28CRP, and 43% (n=34) according to CDAI and 43% (n=34) according to ACR/EULAR 2011 remission criteria. (Table) . 
